Psoriatic Immune Response to Tildrakizumab

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · May 20, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how the immune system responds to a treatment called tildrakizumab in patients with moderate to severe psoriasis, a skin condition that causes red, scaly patches on the skin. The researchers want to understand how this medication, which blocks a specific part of the immune system, affects both the skin and blood cells in people with psoriasis before and after they start treatment.

To participate in this trial, you need to be at least 18 years old and have psoriasis that affects more than 5% of your body. There are some exclusions, such as currently being pregnant, having certain serious infections, or taking specific medications that suppress the immune system in the last month. If you join, you can expect to undergo tests that assess your immune system's function before starting the treatment and again afterward. This study is currently looking for participants, and it's a great opportunity to contribute to our understanding of psoriasis treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older
• • Patients with moderate-severe psoriasis or \> 5% body surface area affected.
• Exclusion Criteria:
• • taking systemic immunosuppressives in the last 4 weeks
• • pregnancy
• • severe immunodeficiency (either from genetic or infectious causes).
• • tuberculosis or other active serious infection
• • active systemic malignancy.
• • breast-feeding
• • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.